Last updated on April 2019

Road to Discovery for Combination Probiotic BB-12 With LGG in Treating Autism Spectrum Disorder


Brief description of study

This study will evaluate the safety and tolerability of combination probiotic BB-12 with LGG in healthy children with autism spectrum disorder aged 4-15 years. Subjects will be randomized to BB-12 with LGG orally (LGG dose: 10^9 c.f.u.'s; BB-12: 10^9) for a total of 56 doses or placebo (maltodextrin) at 2:1 ratio. The time on study treatment is 56 days, and the target sample size is 30 individuals (i.e., 20 in the treatment arm and 10 in the placebo arm).

Clinical Study Identifier: NCT02674984

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.